HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9

Cardiol Therapeutics Inc Ordinary Shares - Class A -4.09% Post

Cardiol Therapeutics Inc Ordinary Shares - Class A

CRDL

2.11

2.07

-4.09%

-1.90% Post

HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Cardiol Therapeutics (NASDAQ: CRDL) with a Buy rating and announces Price Target of $9.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via